A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 29 Apr 2018
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AWARD-10
- Sponsors Eli Lilly
- 26 Feb 2018 Results published in an Eli Lilly Media Release.
- 26 Feb 2018 According to an Eli Lilly media release, data were published online first in The Lancet Diabetes & Endocrinology.
- 26 Feb 2018 Primary endpoint of change from baseline in hemoglobin A1c (HbA1c) at 24 weeks has been met, according to an Eli Lilly media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History